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and T.E. Starzl 
ALTHOUGH graft-versus-host disease (GVHD) has been a major concern after small-bowel transplanta-
tion (SBTX), the lack of suitable experimental model has 
allowed only limited study of GVHD after solid-organ 
transplantation. l We recently developed a clinically rele-
vant experimental animal model of GVHD of fully alloge-
neic SBTX. This study describes histopathological evolution 
of the disease. cytokine involvement, responsible donor 
cells, and preliminary results of treatment using recipient 
and third-party cell infusion. 
MATERIALS AND METHODS 
Lewis (LEW. RTl') rat recipients received orthotopic SBTX and 
simultaneous donor hone marrow cell infusion (BMC, 250 X 10") 
from ACI (RTla) rats. Tacrolimus (FK 506.1 mglkg per day) was 
administered on days 0 to 13, then continued as a weekly injection 
of same dose for 350 days. The number of donor cells in the 
recipient circulation was determined by flow cytometry using 
antibodies specific for donor and recipient MHC class I (MAbs 
MN4-91·6 and 163). Reverse-transcription polymerase chain reac-
tion (RT-PCR) using .'2P-labeled primers was used to measure the 
levels of cytokine mRNA in the graft and recipient tissues. 
RESULTS 
Donor cells persisted in the recipients for more than 300 
days after transplantation and accounted for 5% to 25% of 
lymphocytes in the circulation. The gradual increase of 
donor cells in these animals correlated with the appearance 
of clinical signs of GYHD (skin rash. hyperkeratosis, body 
weight, and hair loss) with a median onset of 104 days 
(range 98 to 114 days). These signs of GYHD waxed and 
waned for the rest of the experimental period. and eventu-
ally all animals died of GVHD or other transplantation-
related complication. such as infection. with a median 
survival of 244 days. Cytokine analysis revealed the associ-
ation of the histopathological changes of GYHD (grades 
1-1II) and the upregulation of IFN--y. TNF-a. IL-6. and 
IL-I () in the cervical lymph nodes and skin before and after 
animals showing clinical signs of GYHD. However. donor 
and recipient small howel in this model did not show any 
increased expression of cytokine mRNA or histopatholog-
ical changes. 
Efficacy of immunomodulatory treatment of GYHD was 
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examined using this GVHD model of SBTX and BMC. In 
vivo ACI (donor strain)-primed splenocytes were prepared 
from LEW (recipient strain) or PVG (third-party strain) 
rats that received simultaneous ACI heart transplantation 
and splenocyte infusion 10 days previously. Infusion of 2.5 
to 3 x lOll in vivo primed splenocytes into GVHD animals 
3 to 5 weeks after the onset of the disease was effective. The 
number of donor cells significantly decreased from pretreat-
ment levels of 25.5 ::!:: 6.1 and 25.1 ::!:: 13.5 to 11.0 ::!:: 6.2 and 
12.5 ::':: 4.1 at 14 to 23 days after infusion with primed 
splenocytes from LEW (n = 2) and PVG (n = 4) animals, 
respectively. 
Clinical signs of GVHD were also significantly improved 
(body weight gain and disappearance of skin rash) in these 
animals. In other groups of animals. fresh unprimed LEW 
or PVG splenocytes (3 x 108 ) were infused into GVHD 
animals at the same timing after the onset of GVHD. These 
recipients showed amelioration of clinical signs of GVHD; 
however, the number of donor cells remained at similar levels. 
CONCLUSIONS 
This study demonstrates a reproducible and clinically rele-
vant animal model of GVHD and a new approach for 
GVHD treatment. The currently available experimental 
GVHD model is artificially based on the one-way paradigm 
of parent to Fl transplantation. in which the recipient 
immune system has been paralyzed. Immunomodulatory 
treatment with in vivo primed recipient or third-party strain 
splenocytes is based on the two-way paradigm of organ 
transplantation2 and will provide a ncw strategy for the 
treatment of GVHD. 
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